Stryker Co. (NYSE:SYK) Shares Purchased by Running Oak Capital LLC

Running Oak Capital LLC boosted its holdings in Stryker Co. (NYSE:SYK) by 16.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,941 shares of the medical technology company’s stock after acquiring an additional 4,384 shares during the period. Stryker accounts for about 1.8% of Running Oak Capital LLC’s investment portfolio, making the stock its 21st largest position. Running Oak Capital LLC’s holdings in Stryker were worth $9,266,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Farmers & Merchants Trust Co of Chambersburg PA lifted its holdings in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares during the period. Rogco LP purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $30,000. HBC Financial Services PLLC acquired a new stake in shares of Stryker during the fourth quarter worth approximately $37,000. Bourgeon Capital Management LLC acquired a new stake in shares of Stryker during the fourth quarter worth approximately $37,000. Finally, Operose Advisors LLC grew its position in shares of Stryker by 308.6% during the third quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after buying an additional 108 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,109 shares of company stock worth $72,845,768. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.5 %

SYK stock traded down $1.49 during midday trading on Thursday, hitting $326.63. The company’s stock had a trading volume of 1,839,474 shares, compared to its average volume of 1,325,064. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company’s fifty day moving average price is $348.05 and its 200 day moving average price is $316.78. The stock has a market capitalization of $124.27 billion, a P/E ratio of 37.27, a PEG ratio of 2.71 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.44%. Stryker’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.14 EPS. As a group, equities research analysts predict that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. Stryker’s dividend payout ratio is presently 36.53%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SYK. Evercore ISI raised their price target on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Truist Financial boosted their price target on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research report on Wednesday, January 31st. UBS Group lifted their price target on Stryker from $339.00 to $351.00 and gave the stock a “neutral” rating in a research note on Wednesday. Barclays boosted their price target on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Roth Mkm boosted their target price on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $359.00.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.